| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
It is well known that IL-22 enhances the barrier mechanism of intestinal mucosa and is deeply involved in inflammatory response control, but it is not known whether it is involved in the mucosal defense mechanism of intractable ulcerative lesions in the small intestine. We confirmed that IEL isolated from mouse produces IL-22 and activates STAT 3 of small intestinal epithelial cells. In addition, in order to investigate the regulatory mechanism of IL-22 production in the small intestine and involvement in the mucosal defense mechanism against small intestinal epithelial cells, it was investigated whether IL-22 produced by IEL could improve mucosal damage of the small intestine induced by indomethacin by using the indomethacin-induced small intestine injury mouse model.
|
